lung cancer gene and literature database Home
Cancer metastasis database

Annotation category 5

Literatures

Literature evidence

Links to all GeneRIF Items

3486

PubMed (Gene Name)

Literature evidence

12011225 (IGFBP3)

Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China.

12068000 (IGFBP3)

Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.

12473575 (IGFBP3)

Hypermethylation of IGFBP-3 promoter is associated with non-small cell lung cancer

18450319 (IGFBP3)

IGFBP-3 promoter polymorphisms of -1590 C>A and -202 A>C might be a genetic risk factor for lung cancer

21254935 (IGFBP3)

The A/A genotype and A allele of the IGFBP-3 promoter -1590 site may represent a genetic risk factor for nonsmall cell lung cancer in a Chinese Han population.

21447628 (IGFBP3)

IGFBP-3 positively and negatively impacts on IGF1-induced lung cancer development.

22347413 (IGFBP3)

Heavy smokers carrying susceptible IGF1, IGF2, and IGFBP3 polymorphisms have a higher risk of lung cancer.

23185474 (IGFBP3)

inverse association was shown between IGFBP-3 and lung cancer in case-control studies; circulating level of IGFBP-3 underwent a decline during tumorogenesis and development of lung cancer, suggesting IGFBP-3 a promising candidate for the biomarker of lung cancer[meta-analysis]

23498137 (IGFBP3)

These results suggest that NNK inhibits IGFBP-3 expression to abrogate anti-tumor actions of the IGFBP-3/IGFBP-3R system in smoking-induced lung cancer.

25482372 (IGFBP3)

The unmethylated IGFBP-3 promoter is associated with resistance to radiotherapy in patients with non-small cell lung cancer.

27071409 (IGFBP3)

Independent of obesity, high insulin levels but reduced levels of IGFBP-3 were associated with increased lung cancer risk in current smokers.

28330997 (IGFBP3)

These findings reveal that IGFBP3 is effective in lung cancer cells with high IGF1 signaling activity and imply that relevant biomarkers are essential in selecting lung cancer patients for IGF1-targeted therapy

31085806 (IGFBP3)

Data provide evidence that up-regulation of IGFBP3 might mediate brain metastasis in lung adenocarcinoma.

31366504 (IGFBP3)

we aimed to evaluate serum levels of IGF-1, IGF-2 and IGF-binding protein 3 (IGF-BP3) before and after standard treatment in patients with advanced non-small cell lung cancer (NSCLC) and their prognostic and predictive correlations.

33436560 (IGFBP3)

circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity.

28330997 (Igfbp3)

Igfbp3-null mouse model was generated in combination with Kras(G12D) to compare the tumor burden. Then, IGF-dependent signaling was assessed after expressing wild-type or a mutant IGFBP3 without IGF binding capacity in non-small cell lung cancer (NSCLC) cells